Show simple item record

dc.contributor.authorNdjeka, N
dc.contributor.authorSchnippel, K
dc.contributor.authorMaster, I
dc.contributor.authorMeintjes, G
dc.contributor.authorMaartens, G
dc.contributor.authorRomero, R
dc.contributor.authorPadanilam, X
dc.contributor.authorEnwerem, M
dc.contributor.authorChotoo, S
dc.contributor.authorSingh, N
dc.contributor.authorHughes, J
dc.contributor.authorVariava, E
dc.contributor.authorFerreira, H
dc.contributor.authorTe Riele, J
dc.contributor.authorIsmail, N
dc.contributor.authorMohr, E
dc.contributor.authorBantubani, N
dc.contributor.authorConradie, F
dc.date.accessioned2018-11-09T14:44:37Z
dc.date.available2018-11-09T14:44:37Z
dc.date.issued2018-10-25
dc.date.submitted2018-11-05
dc.identifier.citationHigh treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. 2018 Eur. Respir. J.en
dc.identifier.issn1399-3003
dc.identifier.pmid30361246
dc.identifier.doi10.1183/13993003.01528-2018
dc.identifier.urihttp://hdl.handle.net/10144/619311
dc.descriptionWe regret that this article is behind a paywall.en
dc.description.abstractBackground: South African patients with rifampicin-resistant tuberculosis and resistance to fluoroquinolones and/or injectables (pre/XDR-TB) were granted access to bedaquiline through a Clinical Access Programme with strict inclusion and exclusion criteria.Methods: Pre/XDR-TB and XDR-TB patients were treated with 24 weeks bedaquiline within an optimised, individualised background regimen that could include levofloxacin, linezolid and clofazimine as needed.Results: 200 patients were enrolled: 87 (43.9%) with XDR-TB, 99 (49.3%) were female, median age 34 years (IQR 27, 42). 134 (67.0%) were living with HIV; median CD4+ 281 (IQR 130; 467) and all on antiretroviral therapy.16/200 patients (8.0%) did not complete 6 months of bedaquiline of which 8 were lost to follow up, 6 died, 1 stopped for side effects and 1 patient was diagnosed with drug-sensitive TB.146/200 (73.0%) patients had favourable outcomes: 139/200 were cured (69.5%) and 7 completed treatment (3.5%). 25 died (12.5%), were lost from treatment (10.0%), 9 had treatment failure (4.5%).22 adverse events were attributed to bedaquiline: including QTcF >500 ms (n=5), QTcF increase >50 ms from baseline (n=11), paroxysmal atrial flutter (n=1).Conclusion: Bedaquiline added to an optimised background regimen was associated with a high rate of successful treatment outcomes for this MDR-TB and XDR-TB cohort.
dc.language.isoenen
dc.publisherEuropean Respiratory Societyen
dc.titleHigh treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimenen
dc.identifier.journalThe European Respiratory Journalen
html.description.abstractBackground: South African patients with rifampicin-resistant tuberculosis and resistance to fluoroquinolones and/or injectables (pre/XDR-TB) were granted access to bedaquiline through a Clinical Access Programme with strict inclusion and exclusion criteria.Methods: Pre/XDR-TB and XDR-TB patients were treated with 24 weeks bedaquiline within an optimised, individualised background regimen that could include levofloxacin, linezolid and clofazimine as needed.Results: 200 patients were enrolled: 87 (43.9%) with XDR-TB, 99 (49.3%) were female, median age 34 years (IQR 27, 42). 134 (67.0%) were living with HIV; median CD4+ 281 (IQR 130; 467) and all on antiretroviral therapy.16/200 patients (8.0%) did not complete 6 months of bedaquiline of which 8 were lost to follow up, 6 died, 1 stopped for side effects and 1 patient was diagnosed with drug-sensitive TB.146/200 (73.0%) patients had favourable outcomes: 139/200 were cured (69.5%) and 7 completed treatment (3.5%). 25 died (12.5%), were lost from treatment (10.0%), 9 had treatment failure (4.5%).22 adverse events were attributed to bedaquiline: including QTcF >500 ms (n=5), QTcF increase >50 ms from baseline (n=11), paroxysmal atrial flutter (n=1).Conclusion: Bedaquiline added to an optimised background regimen was associated with a high rate of successful treatment outcomes for this MDR-TB and XDR-TB cohort.


This item appears in the following Collection(s)

Show simple item record